Home › Funds › Candriam S.C.A. › ALNY

Candriam S.C.A. position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

Candriam S.C.A. reported holding 314,512 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$94.6M, representing 0.43% of its reported portfolio and ranking #46 among its reported holdings. Candriam S.C.A. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)314.51K sh
Reported value held$94.59M
Portfolio Weight0.43%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Candriam S.C.A.'s ALNY position evolved

Candriam S.C.A. first disclosed a stake in ALNY in Q3 2023 at 328,894 shares (US$58.2M). The position peaked in Q3 2025 at 212,416 shares, worth US$96.9M. Across 12 filings, Candriam S.C.A. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 314,512 shares valued at US$94.6M — an increase of 90,182 shares quarter over quarter.. Notable position changes include a 100% trim in Q4 2023 (shares fell 22% over the following quarter), a 751% increase in Q2 2024 (shares rose 13% over the following quarter), a 106108% increase in Q3 2025 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 328.89K $58.25M New
Q4 2023 700 $693.49K Reduce
Q1 2024 800 $754.51K Add
Q2 2024 6.81K $6.56M Add
Q3 2024 520 $608.47K Reduce
Q4 2024 520 $557.35K Hold
Q1 2025 200 $231.02K Reduce
Q2 2025 200 $258.50K Hold
Q3 2025 212.42K $96.86M Add
Q4 2025 224.33K $89.21M Add
Q1 2026 224.33K $74.22M Hold
Q2 2026 314.51K $94.59M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has Candriam S.C.A. held ALNY?

Candriam S.C.A. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Candriam S.C.A.'s current position in ALNY?

As of Q2 2026, Candriam S.C.A. holds 314.51K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $94.59M, representing 0.43% of its reported portfolio and ranking #46.

Has Candriam S.C.A. been buying or selling ALNY?

In the latest 13F filing (Q2 2026), Candriam S.C.A. increased its position in ALNY. The position peaked in Q3 2025 at 212.42K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.